MT921 clinical trials
Also written MT921.
How each study uses MT921 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MT921
- 3
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses MT921 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental FatCompletedPhase 3Medy-ToxNCT05195112Written as MT921
- Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy SubjectsCompletedPhase 1Medy-ToxNCT03905291Written as MT921
- A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental FatCompletedPhase 2Medy-ToxNCT04144049Written as MT921